All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, When should a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternated with methotrexate and cytarabine (hyper-CVAD) regimen be considered for ALL? And when not?
When should a Hyper CVAD regimen be considered for ALL? And when not?
Jabbour begins by outlining how this pediatric inspired regimen became a standard of care. He goes on to explain how by monitoring toxicities, disease and patient profiles, adjustments can be made, e.g. dose variations or drug omissions. He highlights that future treatment is moving away from intensive chemotherapy in favor of further integration of immunotherapy into the regimen.
How should we treat older patients with ALL?
During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, How should we treat older patients with...
Hyper-CVAD with sequential blinatumomab for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative B-cell ALL
Despite high rates of complete remissions, long-term survival in patients with B-cell acute lymphoblastic...
Subscribe to get the best content related to ALL delivered to your inbox